RE:MedImmuneAbout my earlier
MedImmune post I wanted to mention that it's possible that Daiichi Sankyo could establish the relationship with Bioasis independently of AstraZeneca, without consulting them.
I would suggest, though, that it's more likely that Daiichi Sankyo would have informed AstraZeneca, especially if any form of trastuzumab were to be involved in the Bioasis/Daiichi Sankyo collaboration. It's even possible that DS was required to inform or even seek permission from AZ if their Enhertu agreement requires it.
The fact that Bioasis has entered a DS collaboration probably means that AZ supports the DS/xB3 project(s), something that would be expected from AZ given their high praise for xB3 in the MedImmune scientific paper.
Bottom line, if AZ didn't like xB3, I doubt there would be a DS/Bioasis collaboration.
jd